Literature DB >> 26213358

Surgery in oesophago-gastric cancer with metastatic disease: Treatment, prognosis and preoperative patient selection.

T Schmidt1, I Alldinger2, S Blank2, J Klose2, C Springfeld3, L Dreikhausen2, W Weichert4, L Grenacher5, T Bruckner6, F Lordick7, A Ulrich2, M W Büchler2, K Ott8.   

Abstract

BACKGROUND: The role of surgical resection in metastatic oesophago-gastric adenocarcinomas (EGA) is not defined and regularly discussed in interdisciplinary tumour boards. Primary objective of this retrospective study was the outcome of patients after surgery. We additionally evaluated our preoperative prognostic score (PPS) based on tumour grading, clinical response to chemotherapy and presumed R-status.
METHODS: 123 of 811 EGA patients were evaluated as cM1, either confirmed intraoperatively or by imaging. Response evaluation after chemotherapy was performed by endoscopy, CT-scan and histopathologically. The prospectively documented patient and outcome data were analysed retrospectively.
RESULTS: 70 patients with adenocarcinoma of the oesophago-gastric junction and 53 patients with gastric cancer were included. The majority had one M1 site (n = 102). 72 received preoperative chemotherapy (CTx) and 51 underwent primary resection. 11 were explored without resection. 49/112 (40%) had multivisceral resections and 63/112 (56%) were completely resected (R0). 26/72 (36%) were clinical responders and 30 patients had a favourable PPS. Median survival was 20.0 months. Survival was significantly prolonged by resection, especially complete resection, and by preoperative CTx (all p = 0.001). Multivisceral resection, type or number of metastases, or primary tumour localization had no impact on survival. In patients undergoing preoperative CTx, clinical response and the PPS influenced survival significantly. In R0 resected patients, preoperative CTx, clinical response and the PPS remained prognostic.
CONCLUSION: Primary resection without preoperative CTx is not appropriate for metastatic EGA. Subgroups of patients with a favourable PPS with response to CTx may be good candidates for surgical resection in metastatic oesophago-gastric cancer.
Copyright © 2015. Published by Elsevier Ltd.

Entities:  

Keywords:  Gastric cancer; Metastasis; Oesophageal cancer; Prognosis; Surgery

Mesh:

Year:  2015        PMID: 26213358     DOI: 10.1016/j.ejso.2015.05.005

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  17 in total

1.  Postoperative follow-up programs improve survival in curatively resected gastric and junctional cancer patients: a propensity score matched analysis.

Authors:  Leila Sisic; Moritz J Strowitzki; Susanne Blank; Henrik Nienhueser; Sara Dorr; Georg Martin Haag; Dirk Jäger; Katja Ott; Markus W Büchler; Alexis Ulrich; Thomas Schmidt
Journal:  Gastric Cancer       Date:  2017-07-24       Impact factor: 7.370

Review 2.  Intensified neoadjuvant multimodal approach in synchronous liver metastases from gastric cancer: a single institutional experience.

Authors:  L Ceniceros; A Chopitea; F Pardo; F Rotellar; L Arbea; J J Sola; J C Subtil; B Sangro; A Benito; J L Hernández-Lizoain; J Rodríguez
Journal:  Clin Transl Oncol       Date:  2017-10-17       Impact factor: 3.405

Review 3.  [Therapeutic approach in oligometastatic gastric and esophageal cancer].

Authors:  T Schmidt; S P Mönig
Journal:  Chirurg       Date:  2017-12       Impact factor: 0.955

4.  Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEG II): thoracoabdominal or abdominal approach?

Authors:  Susanne Blank; Thomas Schmidt; Patrick Heger; Moritz J Strowitzki; Leila Sisic; Ulrike Heger; Henrik Nienhueser; Georg Martin Haag; Thomas Bruckner; André L Mihaljevic; Katja Ott; Markus W Büchler; Alexis Ulrich
Journal:  Gastric Cancer       Date:  2017-07-06       Impact factor: 7.370

Review 5.  [Oligometastases in gastric and esophageal cancer : Current clinical trials and surgical concepts].

Authors:  S Beckert; A Königsrainer
Journal:  Chirurg       Date:  2018-07       Impact factor: 0.955

6.  Inflammatory cytokines are associated with response and prognosis in patients with esophageal cancer.

Authors:  Susanne Blank; Henrik Nienhüser; Lena Dreikhausen; Leila Sisic; Ulrike Heger; Katja Ott; Thomas Schmidt
Journal:  Oncotarget       Date:  2017-07-18

7.  Prospective randomized controlled trial to compare laparoscopic distal gastrectomy (D2 lymphadenectomy plus complete mesogastrium excision, D2 + CME) with conventional D2 lymphadenectomy for locally advanced gastric adenocarcinoma: study protocol for a randomized controlled trial.

Authors:  Jie Shen; Beibei Cao; Yatao Wang; Aitang Xiao; Jichao Qin; Jianhong Wu; Qun Yan; Yuanlong Hu; Chuanyong Yang; Zhixin Cao; Junbo Hu; Ping Yin; Daxing Xie; Jianping Gong
Journal:  Trials       Date:  2018-08-09       Impact factor: 2.279

8.  Can We Increase the Resection Rate by Minimally Invasive Approach? Experience from 100 Minimally Invasive Esophagectomies.

Authors:  Olli Helminen; Johanna Mrena; Eero Sihvo
Journal:  J Oncol       Date:  2019-02-24       Impact factor: 4.375

9.  Population-based study of anastomotic stricture rates after minimally invasive and open oesophagectomy for cancer.

Authors:  O Helminen; V Kytö; J H Kauppila; J Gunn; J Lagergren; E Sihvo
Journal:  BJS Open       Date:  2019-06-10

10.  Effect of FOLFOX4 combined with Brucea javanica emulsion on VEGF in patients with gastric cancer.

Authors:  Zheng Chen; Zhenyu Zhou; Zhigang Hu; Qiaodong Xu; Jie Wang
Journal:  Oncol Lett       Date:  2017-11-16       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.